Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 known ✓ | P11511 | 2/20 | 0.50 |
| ▸ | ANPEP | P15144 | 5/20 | 0.58 |
| ▸ | IL1RN | P18510 | 1/20 | 0.50 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.50 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2384933 | 0.98 | ANPEP (0.56) | ANPEPCYP19A1IL1RNERAP2ERAP1 | |
| SCHEMBL11865381 | 0.98 | ANPEP (0.56) | ANPEPCYP19A1IL1RNERAP2ERAP1 | |
| SCHEMBL30539234 | 0.98 | ANPEP (0.56) | ANPEPCYP19A1IL1RNERAP2ERAP1 | |
| Hydrochloric Acid SCHEMBL27827926 | 0.80 | ACHE (0.57) | ANPEPCYP19A1 | |
| Hydrochloric Acid SCHEMBL7130904 | 0.80 | ACHE (0.57) | ANPEPCYP19A1 | |
| Hydrochloric Acid SCHEMBL27846771 | 0.80 | ACHE (0.57) | ANPEPCYP19A1 | |
| Hydrochloric Acid SCHEMBL3229886 | 0.80 | MAOB (0.47) | ANPEPIL1RNERAP2ERAP1 | |
| Hydrochloric Acid SCHEMBL3229892 | 0.80 | MAOB (0.47) | ANPEPIL1RNERAP2ERAP1 | |
| SCHEMBL13039620 | 0.78 | DRD2 (0.56) | CYP19A1CES1 | |
| SCHEMBL30539131 | 0.78 | ACHE (0.59) | ANPEPCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569294-B2 | 2-(cyclic amino)-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2423207-A2 | 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-2001863-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES AS TPK1 INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007119463-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES AS TPK1 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-25 | — | — | WO | disclosed |
| US-6927225-B2 | Fungicidal 2-pyridyl alkyl amides and their compositions, methods of use and preparation | DOW AGROSCIENCES LLC (US) | 2005-08-09 | — | — | US | disclosed |
| US-6906098-B2 | Mixed steroidal 1,2,4,5-tetraoxane compounds and methods of making and using thereof | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040019200-A1 | Cycloalkyl-spiro-1, 2,4,5-tetraoxacyclohexane-spiro-cholic acids and derivatives; antiprotozoa agents, bactericides and antitumor agents | ARMY, UNITED STATES | 2004-01-29 | — | — | US | disclosed |
| WO-2003068736-A2 | MIXED STEROIDAL 1,2,4,5-TETRAOXANE COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2003-08-21 | — | — | WO | disclosed |
| US-6521622-B1 | Effective against plant pathogens and wood decaying fungi | DOW AGROSCIENCES LLC | 2003-02-18 | — | — | US | disclosed |
| US-20020177578-A1 | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation | RICKS MICHAEL J (US) | 2002-11-28 | — | — | US | disclosed |
| US-5523306-A | TRYPTOPHAN DERIVATIVES FOR BLOCKING DRUG OR ALCOHOL WITHDRAWAL RESPONSE IN MAMMALS; ANTIPSYCHOTIC, ANTIULCER AGENTS; APPETITE SUPPRESSANTS | WARNER-LAMBERT COMPANY (US) | 1996-06-04 | — | — | US | disclosed |
| US-5397788-A | Antitumor agents, antiulcer agents, antipsychotics or anxiety | WARNER-LAMBERT COMPANY (US) | 1995-03-14 | — | — | US | disclosed |
| EP-0546123-A4 | — | — | 1994-04-27 | — | — | EP | disclosed |
| US-5244915-A | Anxiolytic agents, tryptophan dipeptide derivatives | WARNER-LAMBERT COMPANY (US) | 1993-09-14 | — | — | US | disclosed |
| EP-0546123-A1 | ALPHA-SUBSTITUTED TRYPTOPHANE DIPEPTOID DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 1993-06-16 | — | — | EP | disclosed |
| WO-1992004322-A1 | ALPHA-SUBSTITUTED TRYPTOPHANE DIPEPTOID DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 1992-03-19 | — | — | WO | disclosed |
| US-H753-H | RIGIDIZED OXAZOLE DYES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1990-03-06 | — | — | US | disclosed |
| US-4420480-A | PARKINSONISM, DEPRESSION, HYPOTENSIVES | MERCK & CO., INC. (US) | 1983-12-13 | — | — | US | disclosed |
| EP-0080115-A2 | Hexahydronaphth(1,2-b)-1,4-oxazines, process for their preparation and pharmaceutical formulation containing them | MERCK & CO. INC. (US) | 1983-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177578-A1 | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation | CYP4X1, CYP1A1, NAT1 | CYP19A1 28/4885ANPEP 773/4885IL1RN 2485/4885 |
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MAPT, PRMT1, PSEN1 | CYP19A1 2743/4885ANPEP 1841/4885IL1RN 1350/4885 |
| US-20040019200-A1 | Cycloalkyl-spiro-1, 2,4,5-tetraoxacyclohexane-spiro-cholic acids and derivatives; antiprotozoa agents, bactericides and antitumor agents | PKD1, HCCS, POT1 | CYP19A1 671/4885ANPEP 2896/4885IL1RN 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.